Matrix-specific method validation for quantitative analysis of vitamin C in diverse foods

M. T. Tarragó-Trani,K. Phillips,Marlyn Cotty

DOI: https://doi.org/10.1016/J.JFCA.2012.03.004

2012-05-01

Abstract:

What problem does this paper attempt to address?

Molnupiravir, an Oral Antiviral Treatment for COVID-19

William Fischer,Joseph J. Eron,Wayne Holman,Myron S. Cohen,Lei Fang,Laura J. Szewczyk,Timothy P Sheahan,Ralph Baric,Katie R. Mollan,Cameron R. Wolfe,Elizabeth R. Duke,Masoud M. Azizad,Katyna Borroto-Esoda,David A. Wohl,Amy James Loftis,Paul Alabanza,Felicia Lipansky,Wendy P. Painter

DOI: https://doi.org/10.1101/2021.06.17.21258639

2021-06-17

Abstract:Abstract Background Easily distributed oral antivirals are urgently needed to treat coronavirus disease-2019 (COVID-19), prevent progression to severe illness, and block transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report the results of a Phase 2a trial evaluating the safety, tolerability, and antiviral efficacy of molnupiravir in the treatment of COVID-19 ( ClinicalTrials.gov NCT04405570 ). Methods Eligible participants included outpatients with confirmed SARS-CoV-2 infection and symptom onset within 7 days. Participants were randomized 1:1 to 200 mg molnupiravir or placebo, or 3:1 to molnupiravir (400 or 800 mg) or placebo, twice-daily for 5 days. Antiviral activity was assessed as time to undetectable levels of viral RNA by reverse transcriptase polymerase chain reaction and time to elimination of infectious virus isolation from nasopharyngeal swabs. Results Among 202 treated participants, virus isolation was significantly lower in participants receiving 800 mg molnupiravir (1.9%) versus placebo (16.7%) at Day 3 (p = 0.02). At Day 5, virus was not isolated from any participants receiving 400 or 800 mg molnupiravir, versus 11.1% of those receiving placebo (p = 0.03). Time to viral RNA clearance was decreased and a greater proportion overall achieved clearance in participants administered 800 mg molnupiravir versus placebo (p = 0.01). Molnupiravir was generally well tolerated, with similar numbers of adverse events across all groups. Conclusions Molnupiravir is the first oral, direct-acting antiviral shown to be highly effective at reducing nasopharyngeal SARS-CoV-2 infectious virus and viral RNA and has a favorable safety and tolerability profile.
Olgotrelvir As a Single-Agent Treatment of Nonhospitalized Patients with Covid-19.

Rongmeng Jiang,Bing Han,Wanhong Xu,Xiaoying Zhang,Chunxian Peng,Qiang Dang,Wei Sun,Ling Lin,Yuanlong Lin,Lingyan Fan,Dongqing Lv,Lei Shao,Ying Chen,Yunqing Qiu,Limei Han,Weixiang Kong,Guangming Li,Kai Wang,Jie Peng,Bingliang Lin,Zhaowei Tong,Xiaobo Lu,Lifeng Wang,Feng Gao,Jiemei Feng,Yongxia Li,Xiaojun Ma,Jinxiang Wang,Shanbo Wang,Wei Shen,Chao Wang,Kuan Yan,Zhenhao Lin,Can Jin,Long Mao,Jia Liu,Yulia Kushnareva,Olivia Kotoi,Zhenghong Zhu,Mike Royal,Mark Brunswick,Henry Ji,Xiao Xu,Hongzhou Lu

DOI: https://doi.org/10.1056/evidoa2400026

2024-01-01

NEJM Evidence

Abstract:BACKGROUND:Olgotrelvir is an oral antiviral with dual mechanisms of action targeting severe acute respiratory syndrome coronavirus 2 main protease (i.e., Mpro) and human cathepsin L. It has potential to serve as a single-agent treatment of coronavirus disease 2019 (Covid-19).METHODS:We conducted a phase 3, double-blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of olgotrelvir in 1212 nonhospitalized adult participants with mild to moderate Covid-19, irrespective of risk factors, who were randomly assigned to receive orally either 600 mg of olgotrelvir or placebo twice daily for 5 days. The primary and key secondary end points were time to sustained recovery of a panel of 11 Covid-19-related symptoms and the viral ribonucleic acid (RNA) load. The safety end point was incidence of treatment-emergent adverse events.RESULTS:The baseline characteristics of 1212 participants were similar in the two groups. In the modified intention-to-treat population (567 patients in the placebo group and 558 in the olgotrelvir group), the median time to symptom recovery was 205 hours in the olgotrelvir group versus 264 hours in the placebo group (hazard ratio, 1.29; 95% confidence interval [CI], 1.13 to 1.46; P<0.001). The least squares mean (95% CI) changes of viral RNA load from baseline were -2.20 (-2.59 to -1.81) log10 copies/ml in olgotrelvir-treated participants and -1.40 (-1.79 to -1.01) in participants receiving placebo at day 4. Skin rash (3.3%) and nausea (1.5%) were more frequent in the olgotrelvir group than in the placebo group; there were no treatment-related serious adverse events, and no deaths were reported.CONCLUSIONS:Olgotrelvir as a single-agent treatment significantly improved symptom recovery. Adverse effects were not dose limiting. (Funded by Sorrento Therapeutics, a parent company of ACEA Therapeutics; ClinicalTrials.gov number, NCT05716425.).
Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19

Mohd. Imran,Mandeep Kumar Arora,Syed Mohammed Basheeruddin Asdaq,Shah Alam Khan,Saleh I. Alaqel,Mohammed Kanan Alshammari,Mohammed M. Alshehri,Ahmed Subeh Alshrari,Alreshidi Mateq Ali,Ahmed Muteb Al-shammeri,Bushra Dhuhayyan Alhazmi,Aishah Ali Harshan,Tauquir Alam,Abida,Md. Tauquir Alam,Abida Abida

DOI: https://doi.org/10.3390/molecules26195795

IF: 4.6

2021-09-24

Molecules

Abstract:The COVID-19 pandemic needs no introduction at present. Only a few treatments are available for this disease, including remdesivir and favipiravir. Accordingly, the pharmaceutical industry is striving to develop new treatments for COVID-19. Molnupiravir, an orally active RdRp inhibitor, is in a phase 3 clinical trial against COVID-19. The objective of this review article is to enlighten the researchers working on COVID-19 about the discovery, recent developments, and patents related to molnupiravir. Molnupiravir was originally developed for the treatment of influenza at Emory University, USA. However, this drug has also demonstrated activity against a variety of viruses, including SARS-CoV-2. Now it is being jointly developed by Emory University, Ridgeback Biotherapeutics, and Merck to treat COVID-19. The published clinical data indicate a good safety profile, tolerability, and oral bioavailability of molnupiravir in humans. The patient-compliant oral dosage form of molnupiravir may hit the market in the first or second quarter of 2022. The patent data of molnupiravir revealed its granted compound patent and process-related patent applications. We also anticipate patent filing related to oral dosage forms, inhalers, and a combination of molnupiravir with marketed drugs like remdesivir, favipiravir, and baricitinib. The current pandemic demands a patient compliant, safe, tolerable, and orally effective COVID-19 treatment. The authors believe that molnupiravir meets these requirements and is a breakthrough COVID-19 treatment.

chemistry, multidisciplinary,biochemistry & molecular biology
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

Angélica Jayk Bernal,Monica M. Gomes da Silva,Dany B. Musungaie,Evgeniy Kovalchuk,Antonio Gonzalez,Virginia Delos Reyes,Alejandro Martín-Quirós,Yoseph Caraco,Angela Williams-Diaz,Michelle L. Brown,Jiejun Du,Alison Pedley,Christopher Assaid,Julie Strizki,Jay A. Grobler,Hala H. Shamsuddin,Robert Tipping,Hong Wan,Amanda Paschke,Joan R. Butterton,Matthew G. Johnson,Carisa De Anda

DOI: https://doi.org/10.1056/NEJMoa2116044

2021-12-18

Abstract:The coronavirus disease 2019 (Covid-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has seen almost 270 million confirmed cases and over 5.2 million reported deaths worldwide. 1 A substantial portion of patients with Covid-19 need hospitalization, predominantly older adults and persons with preexisting conditions (e.g., obesity, diabetes mellitus, and serious cardiac conditions). 2-4 Several vaccines that are highly effective in reducing the incidence of hospitalization and death have been authorized; however, vaccine coverage remains insufficient. 5,6 Antiviral therapies that reduce the risk of Covid-19 progression are needed. Since trials have shown the need for initiation of treatment as soon as possible after the onset of symptoms, 7-9 such therapies would ideally be readily available and easily administered by the patients themselves. 10,11
Molnupiravir: Mechanism of action, clinical, and translational science

Brian M. Maas,Julie Strizki,Randy R. Miller,Sushma Kumar,Michelle Brown,Matthew G. Johnson,Mickie Cheng,Carisa De Anda,Matthew L. Rizk,Julie A. Stone

DOI: https://doi.org/10.1111/cts.13732

2024-02-10

Clinical and Translational Science

Abstract:Molnupiravir is an oral prodrug of the broadly active, antiviral ribonucleoside analog N‐hydroxycytidine (NHC). The primary circulating metabolite NHC is taken up into cells and phosphorylated to NHC‐triphosphate (NHC‐TP). NHC‐TP serves as a competitive substrate for viral RNA‐dependent RNA polymerase (RdRp), which results in an accumulation of errors in the viral genome, rendering virus replication incompetent. Molnupiravir has demonstrated activity against SARS‐CoV‐2 both clinically and preclinically and has a high barrier to development of viral resistance. Little to no molnupiravir is observed in plasma due to rapid hydrolysis to NHC. Maximum concentrations of NHC are reached at 1.5 h following administration in a fasted state. The effective half‐life of NHC is 3.3 h, reflecting minimal accumulation in the plasma following twice‐daily (Q12H) dosing. The terminal half‐life of NHC is 20.6 h. NHC‐TP exhibits a flatter profile with a lower peak‐to‐trough ratio compared with NHC, which supports Q12H dosing. Renal and hepatic pathways are not major routes of elimination, as NHC is primarily cleared by metabolism to uridine and cytidine, which then mix with the endogenous nucleotide pools. In a phase III study of nonhospitalized patients with COVID‐19 (MOVe‐OUT), 5 days of treatment with 800 mg molnupiravir Q12H significantly reduced the incidence of hospitalization or death compared with placebo. Patients treated with molnupiravir also had a greater reduction in SARS‐CoV‐2 viral load and improved clinical outcomes, compared with those receiving placebo. The clinical effectiveness of molnupiravir has been further demonstrated in several real‐world evidence studies. Molnupiravir is currently authorized or approved in more than 25 countries.

medicine, research & experimental
The Benefits of Molnupiravir Treatment in Healthcare Facilities Patients with COVID-19

Shih-Lung Cheng,Ping-Huai Wang,Cheng-Yu Chang,Hsu-Hui Wang,Chung-Jen Wang,Kuan-Ming Chiu

DOI: https://doi.org/10.2147/dddt.s392708

2023-01-19

Abstract:Shih-Lung Cheng, 1, 2 Ping-Huai Wang, 1 Cheng-Yu Chang, 1 Hsu-Hui Wang, 1 Chung-Jen Wang, 1 Kuan-Ming Chiu 2, 3 1 Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, 220, Taiwan; 2 The Graduate Institute of Medicine, Yuan-Ze University, Taoyuan City, Taiwan; 3 Division of Cardiovascular Surgery, Far Eastern Memorial Hospital, New Taipei City, 220, Taiwan Correspondence: Kuan-Ming Chiu, Division of Cardiovascular Surgery, Far Eastern Memorial Hospital, No. 21, Section 2, Nanya S. Road, Banqiao District, New Taipei City, 220, Taiwan, Tel +886-2-89667000, Email Background: Molnupiravir (MOL) is an oral antiviral medication that has recently been treated for COVID-19. Objectively: We perform a prospective and observational study to elucidate the efficacy and safety of MOL in healthcare patients with COVID-19. Materials and Methods: A observational, non-randomized study of patients diagnosed with COVID-19 in 46 healthcare facilities and treated with MOL started within 5 days after the onset of signs or symptoms. We recorded data for all patients, including demographic data, clinical features, and symptoms. Treatment response was classified into cure, stable, hospitalization and death. Multivariate analysis was performed with stepwise logistic regression for hospitalization and death risk factors. Results: In total, 856 patients were diagnosed as having COVID-19 and treated with MOL during the study period. Of those, 496 patients (57.9%) were cured, 256 patients (29.9%) in stable condition, 104 patients (12.2%) hospitalized, and 22 patients (2.6%) died, respectively. There was significant effectiveness (87.8%) in COVID-19 patients using MOL. Multivariate analysis was performed to confirm the risk factors for hospitalization and death and included elder age (> 80 years old) (odds ratio (OR) 2.2, 95% confidence interval (CI): 1.1– 6.9), old cerebrovascular accident (CVA) (OR=4.1, 95% CI: 1.3– 9.9), the presence of diabetes mellitus (DM) (OR=2.6, 95% CI: 1.2– 9.1) and chronic respiratory diseases (OR=2.4, 95% (CI): 1.3– 8.1). Limitations: This is an observational study, neither randomized study nor control group study. Conclusion: Initial treatment with MOL has the treatment benefits and is well tolerated for patients with COVID-19 in healthcare facilities. Older age, old CVA, DM, and chronic respiratory diseases were independent risk factors for hospitalization and mortality. The results demonstrate there are important clinical benefits of MOL beyond the reduction in hospitalization or death for these patients with more comorbidities in Taiwan. Keywords: molnupiravir, COVID-19, healthcare facility, clinical benefit, hospitalization, comorbidity COVID-19 infection is currently affected among the general population in the world. This disease was first documented in Wuhan (China) in December 2019 and is due to SARS-CoV-2 (2019-nCoV) virus. COVID-19 symptoms included high body temperature, general malaise, sore throat, cough, shortness of breath, low energy status. In most infected people, the symptoms are mild, but in the elderly or those with multiple comorbidities it may complicate with severe pneumonia, acute respiratory distress syndrome, multi-organ failure, and death. 1 Adequate vaccines' administration is important for the prevention of severe COVID-19 development or mortality; however, the effective antiviral medications to combat this disease are not currently available. Patients with immunocompromised diseases could not be fully protected though got vaccinated, and existing vaccines may not be good protection against new SARS-CoV-2 variants. 2,3 Remdesivir, a new antiviral agent, has been demonstrated that there were beneficial effects in antiviral treatment 4 ; however, some studies have not documented its effectiveness on coronavirus therapy. Most important, the drug is expensive and can just be administered intravenously in a hospital facility. 4–6 For convenience and popularity, there is the need to develop simple oral anti-virus drugs available in most patients with COVID-19 infection. Three are new oral antiviral medications developed and have documented clinical effectiveness in recent studies. Among these oral medications, molnupiravir (MOL), a new orally active RdRp inhibitor with a excellent pharmacokinetic character, has demonstrated to have its ability to interfere SARS-COV-2 replication, and reduce viral load. 4 MOL has the unique agent with the isopropyl ester prodrug of the ribonucleoside analogue β-D-N4-hydroxycytidine (NHC). 7 Previous studies have found that MOL is -Abstract Truncated-

pharmacology & pharmacy,chemistry, medicinal
Molnupiravir: A new candidate for COVID‐19 treatment

Fariba Pourkarim,Samira Pourtaghi‐Anvarian,Haleh Rezaee

DOI: https://doi.org/10.1002/prp2.909

2021-12-30

Abstract:The novel coronavirus disease 2019 (COVID-19) emerged in late December 2019 in china and has rapidly spread to many countries around the world. The effective pharmacotherapy can reduce the mortality of COVID-19. Antiviral medications are the candidate therapies for the management of COVID-19. Molnupiravir is an antiviral drug with anti-RNA polymerase activity and currently is under investigation for the treatment of patients with COVID-19. This review focuses on summarizing published literature for the mechanism of action, safety, efficacy, and clinical trials of molnupiravir in the treatment of COVID-19 patients.

pharmacology & pharmacy
Antiviral Efficacy of Molnupiravir for COVID-19 Treatment.

Yuan Bai,Mingwang Shen,Lei Zhang

DOI: https://doi.org/10.3390/v14040763

2022-01-01

Viruses

Abstract:The ongoing global pandemic of COVID-19 poses unprecedented public health risks for governments and societies around the world, which have been exacerbated by the emergence of SARS-CoV-2 variants. Pharmaceutical interventions with high antiviral efficacy are expected to delay and contain the COVID-19 pandemic. Molnupiravir, as an oral antiviral prodrug, is active against SARS-CoV-2 and is now (23 February 2022) one of the seven widely-used coronavirus treatments. To estimate its antiviral efficacy of Molnupiravir, we built a granular mathematical within-host model. We find that the antiviral efficacy of Molnupiravir to stop the growth of the virus is 0.56 (95% CI: 0.49, 0.64), which could inhibit 56% of the replication of infected cells per day. There has been good progress in developing high-efficacy antiviral drugs that rapidly reduce viral load and may also reduce the infectiousness of treated cases if administered as early as possible.
A Systematic Review of Nirmatrelvir/Ritonavir and Molnupiravir for the Treatment of Coronavirus Disease 2019

Alyson Haslam,Vinay Prasad

DOI: https://doi.org/10.1093/ofid/ofae497

2024-09-07

Abstract:Background: To address the need for treatments for patients with coronavirus disease 2019 (COVID-19), 3 therapies have been given either full approval or Emergency Use Authorization. These were based on randomized data showing a reduction in deaths/hospitalization, but since then, circulating viral strains and population immunity have changed. Methods: We searched PubMed, Web of Science, Embase, and ClinicalTrials.gov for clinical trials testing nirmatrelvir/ritonavir and molnupiravir for COVID-19. We identified all trials testing nirmatrelvir/ritonavir and molnupiravir in patients with COVID-19 and assessed the pooled efficacy in a meta-analysis. We calculated pooled estimates of hospitalization and death in patients with COVID-19 and the number of studies with published/reported data. Results: Of the 23 studies found, 11 tested nirmatrelvir/ritonavir, 10 tested molnupiravir, and 2 tested both agents. The pooled estimate in reducing deaths and hospitalization for molnupiravir was 0.62 (95% confidence interval [CI], 0.15-2.53), and the pooled estimate for nirmatrelvir/ritonavir was 0.33 (95% CI, 0.03-3.35). The 1 nirmatrelvir/ritonavir trial that reported significant improvements tested people who were predominantly infected with earlier COVID-19 variants, whereas the 2 null trials were tested in people infected with more recent variants. The 2 positive molnupiravir trials included participants primarily with the Delta variant, whereas the null trials were tested later, against more recent variants. Conclusions: While early trial data show effectiveness of these therapies, the overall pooled effects are nonsignificant, suggesting that recommendations and use of approved oral COVID-19 treatment therapies need to be reevaluated in the context of current viral strains and population immunity.
Antiviral Efficacy and Safety of Molnupiravir Against Omicron Variant Infection: A Randomized Controlled Clinical Trial

Rongrong Zou,Ling Peng,Dan Shu,Lei Zhao,Jianfeng Lan,Guoyu Tan,Jinghan Peng,Xiangyi Yang,Miaona Liu,Chenhui Zhang,Jing Yuan,Huxiang Wang,Song Li,Hongzhou Lu,Wu Zhong,Yingxia Liu

DOI: https://doi.org/10.3389/fphar.2022.939573

IF: 5.6

2022-01-01

Frontiers in Pharmacology

Abstract:Background: The rapid worldwide spread of the Omicron variant of SARS-CoV-2 has unleashed a new wave of COVID-19 outbreaks. The efficacy of molnupiravir, an approved drug, is still unknown in patients infected with the Omicron variant.Objective: Evaluated the antiviral efficacy and safety of molnupiravir in patients infected with SARS-CoV-2 Omicron variant, with symptom duration within 5 days. Methods: We conducted a randomized, controlled trial involving patients with mild or moderate COVID-19. Patients were randomized to orally receive molnupiravir (800 mg) plus basic treatment or only basic treatment for 5 days (BID). The antiviral efficacy of the drug was evaluated using reverse transcriptase polymerase chain reaction. Results: Results showed that the time of viral RNA clearance (primary endpoint) was significantly decreased in the molnupiravir group (median, 9 days) compared to the control group (median, 10 days) (Log-Rank p = 0.0092). Of patients receiving molnupiravir, 18.42% achieved viral RNA clearance on day 5 of treatment, compared to the control group (0%) (p = 0.0092). On day 7, 40.79%, and 6.45% of patients in the molnupiravir and control groups, respectively, achieved viral RNA clearance (p = 0.0004). In addition, molnupiravir has a good safety profile, and no serious adverse events were reported. Conclusion: Molnupiravir significantly accelerated the SARS-CoV-2 Omicron RNA clearance in patients with COVID-19.
Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19

Matthew G. Johnson,Amy Puenpatom,Pablo Andrés Moncada,Lesley Burgess,Elizabeth R. Duke,Norio Ohmagari,Timo Wolf,Matteo Bassetti,Sanjay Bhagani,Jade Ghosn,Ying Zhang,Hong Wan,Angela Williams-Diaz,Michelle L. Brown,Amanda Paschke,Carisa De Anda

DOI: https://doi.org/10.7326/m22-0729

IF: 39.2

2022-06-08

Annals of Internal Medicine

Abstract:In the MOVe-OUT trial, molnupiravir showed a clinically meaningful reduction in the risk for hospitalization or death in adults with mild to moderate COVID-19 and risk factors for progression to severe disease. To identify other potential clinical benefits of molnupiravir versus placebo. Secondary analysis of the randomized, double-blind, placebo-controlled phase 3 component of MOVe-OUT. (ClinicalTrials.gov: NCT04575597) 107 sites globally. 1433 nonhospitalized adults aged 18 years or older with mild to moderate COVID-19. Molnupiravir, 800 mg, or placebo every 12 hours for 5 days. Changes from baseline in C-reactive protein (CRP) concentration and oxygen saturation (Sp o 2 ), need for respiratory interventions (including invasive mechanical ventilation), and need for medical services in all randomly assigned participants through day 29, and need for respiratory interventions and time to discharge in the subgroup of participants who were hospitalized after randomization. Participants receiving molnupiravir showed faster normalization of CRP and Sp o 2 , with improvements observed on day 3 of therapy, compared with placebo. Molnupiravir-treated participants had a decreased need for respiratory interventions versus placebo-treated participants (relative risk reduction [RRR], 34.3% [95% CI, 4.3% to 54.9%]), with similar findings in participants who were hospitalized after randomization (RRR, 21.3% [CI, 0.2% to 38.0%]). Hospitalized participants who received molnupiravir were discharged a median of 3 days before those who received placebo. Acute care visits (7.2% vs. 10.6%; RRR, 32.1% [CI, 4.4% to 51.7%]) and COVID-19–related acute care visits (6.6% vs. 10.0%; RRR, 33.8% [CI, 5.6% to 53.6%]) were less frequent in molnupiravir- versus placebo-treated participants. Some analyses were performed post hoc. Longer-term benefits of molnupiravir therapy were not evaluated. Participants were not immunized against SARS-CoV-2. The findings suggest there are additional important clinical benefits of molnupiravir beyond reduction in hospitalization or death. Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.

medicine, general & internal
Molnupiravir or nirmatrelvir-ritonavir versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Peter W Horby,Natalie Staplin,Leon Peto,Jonathan R Emberson,Mark Campbell,Guilherme Pessoa-Amorim,Buddha Basnyat,Louise Thwaites,Rogier Van Doorn,Raph L Hamers,Jeremy Nel,John Amuasi,Richard Stewart,Dipansu Ghosh,Fergus Hamilton,Purav Desai,Nicholas Easom,Jaydip Majumdar,Paul Hine,David Chadwick,Graham Cooke,Sara Sharp,Hanif Esmail,J Kenneth Baillie,Maya H Buch,Saul N Faust,Thomas Jaki,Katie Jeffery,Edmund Juszczak,Marian Knight,Wei Shen Lim,Alan Montgomery,Aparna Mukherjee,Andrew Mumford,Kathryn Rowan,Guy Thwaites,Marion Mafham,Richard Haynes,Martin J Landray

DOI: https://doi.org/10.1101/2024.05.23.24307731

2024-05-24

Abstract:Background: Molnupiravir and nirmatrelvir-ritonavir (Paxlovid) are oral antivirals that have been proposed as treatments for patients admitted to hospital with COVID-19. Methods: In this randomised, controlled, open-label, adaptive platform trial, several potential treatments for patients hospitalised with COVID-19 pneumonia were evaluated. Molnupiravir and nirmatrelvir-ritonavir were assessed in separate comparisons in RECOVERY, both of which are reported here. Eligible and consenting adults could join the molnupiravir comparison, the nirmatrelvir-ritonavir comparison, or both. For each comparison, participants were randomly allocated in a 1:1 ratio to the relevant antiviral (five days of molnupiravir 800mg twice daily or nirmatrelvir-ritonavir 300mg/100mg twice daily) or to usual care without the relevant antiviral drug, using web-based unstratified randomisation with allocation concealment. The primary outcome was 28-day mortality, and secondary outcomes were time to discharge alive from hospital, and among those not on invasive ventilation at baseline, progression to invasive ventilation or death. Analysis was by intention-to-treat. Both comparisons were stopped by the investigators because of low recruitment. ISRCTN (50189673) and clinicaltrials.gov ( ). Findings: From 24 January 2022 to 24 May 2023, 923 patients were recruited to the molnupiravir comparison (445 allocated molnupiravir and 478 allocated usual care), and from 31 March 2022 to 24 May 2023, 137 patients were recruited to the nirmatrelvir-ritonavir comparison (68 allocated nirmatrelvir-ritonavir and 69 allocated usual care). More than three-quarters of the patients in both comparisons were vaccinated and had anti-spike antibodies at randomisation, and more than two-thirds were receiving other SARS-CoV-2 antivirals (including remdesivir or sotrovimab). In the molnupiravir comparison, 74 (17%) patients allocated to molnupiravir and 79 (17%) patients allocated usual care died within 28 days (hazard ratio [HR] 0.93; 95% confidence interval [CI] 0.68-1.28; p=0.66). In the nirmatrelvir-ritonavir comparison, 13 (19%) patients allocated nirmatrelvir-ritonavir and 13 (19%) patients allocated usual care died within 28 days (HR 1.02; 95% CI 0.47-2.23; p=0.96). In neither comparison was there evidence of a significant difference in the duration of hospitalisation or the proportion of patients progressing to invasive ventilation or death. Interpretation: In adults hospitalised with COVID-19, neither molnupiravir nor nirmatrelvir-ritonavir were associated with reductions in 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death although these comparisons had limited statistical power due to low recruitment.
Molnupiravir Use Among Patients with COVID-19 in Real-World Settings: A Systematic Literature Review

Raziano, Valerie T.

DOI: https://doi.org/10.1007/s40121-024-00976-5

2024-05-15

Infectious Diseases and Therapy

Abstract:Molnupiravir (MOV) is an oral antiviral for the treatment of individuals with mild-to-moderate COVID-19 and at high risk of progression to severe disease. Our objective was to conduct a systematic literature review (SLR) of evidence on the effectiveness of MOV in reducing the risk of severe COVID-19 outcomes in real-world outpatient settings.

infectious diseases
Suggestions on therapeutic urology.

M. B. Wesson

Abstract:
Determining and Comparing the Real-World Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Patients Hospitalized With COVID-19

Young Rock Jang,Yoonju Oh,Jin Yong Kim

DOI: https://doi.org/10.3346/jkms.2024.39.e52

2024-01-01

Journal of Korean Medical Science

Abstract:BACKGROUND: Current guidelines recommend using nirmatrelvir-ritonavir for coronavirus disease 2019 (COVID-19) treatment, but its potential drug interactions and contraindications limit its applicability in certain categories of patients. The aim of the study was to evaluate the real-world effectiveness of molnupiravir and nirmatrelvir-ritonavir in managing COVID-19 among hospitalized patients.METHODS: We conducted a retrospective cohort study among hospitalized COVID-19 patients who received molnupiravir or nirmatrelvir-ritonavir and did not require baseline supplemental oxygen from February 2022 to January 2023. We compared the effectiveness of molnupiravir and nirmatrelvir-ritonavir with a focus on disease progression.RESULTS: The study included 401 high-risk, hospitalized adult COVID-19 patients who received molnupiravir or nirmatrelvir-ritonavir. No significant difference was found in disease progression, the composite outcome of disease progression (4.0% vs. 1.4%, P = 0.782), and O2 supplementation via nasal prong (21.8% vs. 14.8%, P = 0.115) between the patients treated with molnupiravir and those treated with nirmatrelvir-ritonavir. This finding was similar after 1:1 propensity-score matching. In the multivariate analysis, molnupiravir treatment was not significantly associated with progression to severe disease.CONCLUSION: In conclusion, our findings suggest that similar to nirmatrelvir-ritonavir, molnupiravir has a distinct potential role in COVID-19 treatment, transcending its current perceived status as only a secondary option.

medicine, general & internal
Why Molnupiravir Fails in Hospitalized Patients

Ashley N Brown,Yinzhi Lang,Jieqiang Zhou,Evelyn J Franco,Kaley C Hanrahan,Juergen B Bulitta,George L Drusano

DOI: https://doi.org/10.1128/mbio.02916-22

IF: 6.4

2022-12-20

mBio

Abstract:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has radically altered daily life. Effective antiviral therapies to combat COVID-19, especially severe disease, remain scarce. Molnupiravir is an antiviral that has shown clinical efficacy against mild-to-moderate COVID-19 but failed to provide benefit to hospitalized patients with severe disease. Here, we explained the mechanism behind the failure of molnupiravir in hospitalized patients and identified alternative dosing strategies that would improve therapeutic outcomes in all patients with COVID-19. We showed that delaying therapy initiation markedly decreased the antiviral effect of molnupiravir, and these results were directly related to intracellular drug triphosphate pools and intracellular viral burden at the start of therapy. The adverse influence of therapeutic delay could be overcome by increasing drug exposure, which increased intracellular molnupiravir triphosphate concentrations that inhibited viral replication. These findings illustrated that molnupiravir must be administered as early as possible following COVID-19 symptom onset to maximize therapeutic efficacy. Higher doses may be effective in patients hospitalized with severe disease, but the safety of high-dose molnupiravir regimens is unknown. Our findings could be extended to design effective regimens with nucleoside analogs for other RNA viruses, especially those with pandemic potential. IMPORTANCE In this study, we showed that early intervention with molnupiravir resulted in a greater antiviral effect, and we explained the mechanism behind this phenomenon. Our results predicted and explained the failure of molnupiravir in hospitalized patients and highlighted the utility of preclinical pharmacodynamic studies to design optimal antiviral regimens for the treatment of viral diseases. This contrasts with the procedure that was implemented early in the pandemic in which clinical studies were conducted in the absence of preclinical experimentation. These findings are significant and demonstrated the importance of experimental approaches in antiviral development for treatments against COVID-19 as well as other viral diseases.
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study

Saye H Khoo,Richard Fitzgerald,Thomas Fletcher,Sean Ewings,Thomas Jaki,Rebecca Lyon,Nichola Downs,Lauren Walker,Olana Tansley-Hancock,William Greenhalf,Christie Woods,Helen Reynolds,Ellice Marwood,Pavel Mozgunov,Emily Adams,Katie Bullock,Wayne Holman,Marcin D Bula,Jennifer L Gibney,Geoffrey Saunders,Andrea Corkhill,Colin Hale,Kerensa Thorne,Justin Chiong,Susannah Condie,Henry Pertinez,Wendy Painter,Emma Wrixon,Lucy Johnson,Sara Yeats,Kim Mallard,Mike Radford,Keira Fines,Victoria Shaw,Andrew Owen,David G Lalloo,Michael Jacobs,Gareth Griffiths

DOI: https://doi.org/10.1093/jac/dkab318

2021-11-12

Abstract:Objectives: AGILE is a Phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in participants with early symptomatic infection. Methods: We undertook a dose-escalating, open-label, randomized-controlled (standard-of-care) Bayesian adaptive Phase I trial at the Royal Liverpool and Broadgreen Clinical Research Facility. Participants (adult outpatients with PCR-confirmed SARS-CoV-2 infection within 5 days of symptom onset) were randomized 2:1 in groups of 6 participants to 300, 600 and 800 mg doses of molnupiravir orally, twice daily for 5 days or control. A dose was judged unsafe if the probability of 30% or greater dose-limiting toxicity (the primary outcome) over controls was 25% or greater. Secondary outcomes included safety, clinical progression, pharmacokinetics and virological responses. Results: Of 103 participants screened, 18 participants were enrolled between 17 July and 30 October 2020. Molnupiravir was well tolerated at 300, 600 and 800 mg doses with no serious or severe adverse events. Overall, 4 of 4 (100%), 4 of 4 (100%) and 1 of 4 (25%) of the participants receiving 300, 600 and 800 mg molnupiravir, respectively, and 5 of 6 (83%) controls, had at least one adverse event, all of which were mild (≤grade 2). The probability of ≥30% excess toxicity over controls at 800 mg was estimated at 0.9%. Conclusions: Molnupiravir was safe and well tolerated; a dose of 800 mg twice daily for 5 days was recommended for Phase II evaluation.
Molnupiravir and Nirmatrelvir-Ritonavir: Oral COVID Antiviral Drugs

Louis D Saravolatz,Shawn Depcinski,Mamta Sharma

DOI: https://doi.org/10.1093/cid/ciac180

IF: 20.999

2022-03-04

Clinical Infectious Diseases

Abstract:Abstract At a crucial time with rapid spread of Omicron SARS-CoV-2 virus variant globally, the United States Food and Drug Administration has issued an emergency use authorization for two oral antivirals molnupiravir (>18 years) and nirmatrelvir-ritonavir (Paxlovid) (≥12 years; >40kg ) for the outpatient treatment of mild to moderate COVID–19 patients who are at risk for progression. Molnupiravir is a nucleoside analogue, whereas nirmatrelvir is a SARS-CoV-2 main protease inhibitor, and ritonavir is an HIV-1 protease inhibitor. Drug interactions are a major concern for nirmatrelvir-ritonavir. Nirmatrelvir-ritonavir demonstrated a greater risk reduction in hospitalization and death than molnupiravir compared to placebo. Both drugs need to be started within five days of symptoms onset and given for five days duration. This article will review the two oral COVID-19 antiviral drugs including the mechanisms of action, antiviral activity, pharmacokinetics, drug interactions, clinical experience including trials, adverse events, recommended indications, and formulary considerations.

immunology,infectious diseases,microbiology
Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients

Joseph F. Standing,Laura Buggiotti,Jose Afonso Guerra-Assuncao,Maximillian Woodall,Samuel Ellis,Akosua A. Agyeman,Charles Miller,Mercy Okechukwu,Emily Kirkpatrick,Amy I. Jacobs,Charlotte A. Williams,Sunando Roy,Luz M. Martin-Bernal,Rachel Williams,Claire M. Smith,Theo Sanderson,Fiona B. Ashford,Beena Emmanuel,Zaheer M. Afzal,Adrian Shields,Alex G. Richter,Jienchi Dorward,Oghenekome Gbinigie,Oliver Van Hecke,Mark Lown,Nick Francis,Bhautesh Jani,Duncan B. Richards,Najib M. Rahman,Ly-Mee Yu,Nicholas P. B. Thomas,Nigel D. Hart,Philip Evans,Monique Andersson,Gail Hayward,Kerenza Hood,Jonathan S. Nguyen-Van-Tam,Paul Little,F. D. Richard Hobbs,Saye Khoo,Christopher Butler,David M. Lowe,Judith Breuer,Julie Allen,Nadua Bayzid,Julianne Brown,Doug Burns,Elizabeth Hadley,Jim Hatcher,Tim McHugh,Chris Thalasselis,Mia Tomlinson,Francis Yongblah,

DOI: https://doi.org/10.1038/s41467-024-45641-0

IF: 16.6

2024-02-23

Nature Communications

Abstract:Abstract Viral clearance, antibody response and the mutagenic effect of molnupiravir has not been elucidated in at-risk populations. Non-hospitalised participants within 5 days of SARS-CoV-2 symptoms randomised to receive molnupiravir (n = 253) or Usual Care (n = 324) were recruited to study viral and antibody dynamics and the effect of molnupiravir on viral whole genome sequence from 1437 viral genomes. Molnupiravir accelerates viral load decline, but virus is detectable by Day 5 in most cases. At Day 14 (9 days post-treatment), molnupiravir is associated with significantly higher viral persistence and significantly lower anti-SARS-CoV-2 spike antibody titres compared to Usual Care. Serial sequencing reveals increased mutagenesis with molnupiravir treatment. Persistence of detectable viral RNA at Day 14 in the molnupiravir group is associated with higher transition mutations following treatment cessation. Viral viability at Day 14 is similar in both groups with post-molnupiravir treated samples cultured up to 9 days post cessation of treatment. The current 5-day molnupiravir course is too short. Longer courses should be tested to reduce the risk of potentially transmissible molnupiravir-mutated variants being generated. Trial registration: ISRCTN30448031

multidisciplinary sciences
Molnupiravir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records

Yan Xie,Benjamin Bowe,Ziyad Al-Aly

DOI: https://doi.org/10.1136/bmj-2022-072705

2023-03-07

BMJ

Abstract:Abstract Objective To emulate a randomized target trial to estimate the association between the antiviral drug molnupiravir and hospital admission or death in adults with SARS-CoV-2 infection in the community during the omicron predominant era who were at high risk of progression to severe covid-19. Design Emulation of a randomized target trial using electronic health records. Setting US Department of Veterans Affairs. Participants 85 998 adults with SARS-CoV-2 infection between 5 January and 30 September 2022 and at least one risk factor for progression to severe covid-19: 7818 participants were eligible for and treated with molnupiravir and 78 180 received no treatment. Main outcomes measure The primary outcome was a composite of hospital admission or death at 30 days. The clone method with inverse probability of censoring weighting was used to adjust for informative censoring and balance baseline characteristics between the groups. The cumulative incidence function was used to estimate the relative risk and the absolute risk reduction at 30 days. Results Molnupiravir was associated with a reduction in hospital admissions or death at 30 days (relative risk 0.72 (95% confidence interval 0.64 to 0.79)) compared with no treatment; the event rates for hospital admission or death at 30 days were 2.7% (95% confidence interval 2.5% to 3.0%) for molnupiravir and 3.8% (3.7% to 3.9%) for no treatment; the absolute risk reduction was 1.1% (95% confidence interval 0.8% to 1.4%). Molnupiravir appeared to be effective in those who had not been vaccinated against covid-19 (relative risk 0.83 (0.70 to 0.97) and absolute risk reduction 0.9% (0.2% to 1.9%)), had received one or two vaccine doses (0.69 (0.56 to 0.83) and 1.3% (0.7% to 1.9%)), and had received a booster dose (0.71 (0.58 to 0.83) and 1.0% (0.5% to 1.4%)); in those infected during the era when the omicron subvariant BA.1 or BA.2 was predominant (0.72 (0.62 to 0.83) and 1.2% (0.7% to 1.6%)) and when BA.5 was predominant (0.75 (0.66 to 0.86) and 0.9% (0.5% to 1.3%)); and in those with no history of SARS-CoV-2 infection (0.72 (0.64 to 0.81) and 1.1% (0.8% to 1.4%)) and with a history of SARS-CoV-2 infection (0.75 (0.58 to 0.97) and 1.1% (0.1% to 1.8%)). Conclusions The findings of this emulation of a randomized target trial suggest that molnupiravir might have reduced hospital admission or death at 30 days in adults with SARS-CoV-2 infection in the community during the recent omicron predominant era who were at high risk of progression to severe covid-19 and eligible for treatment with molnupiravir.

medicine, general & internal

Matrix-specific method validation for quantitative analysis of vitamin C in diverse foods

Molnupiravir, an Oral Antiviral Treatment for COVID-19

Olgotrelvir As a Single-Agent Treatment of Nonhospitalized Patients with Covid-19.

Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

Molnupiravir: Mechanism of action, clinical, and translational science

The Benefits of Molnupiravir Treatment in Healthcare Facilities Patients with COVID-19

Molnupiravir: A new candidate for COVID‐19 treatment

Antiviral Efficacy of Molnupiravir for COVID-19 Treatment.

A Systematic Review of Nirmatrelvir/Ritonavir and Molnupiravir for the Treatment of Coronavirus Disease 2019

Antiviral Efficacy and Safety of Molnupiravir Against Omicron Variant Infection: A Randomized Controlled Clinical Trial

Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19

Molnupiravir or nirmatrelvir-ritonavir versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Molnupiravir Use Among Patients with COVID-19 in Real-World Settings: A Systematic Literature Review

Suggestions on therapeutic urology.

Determining and Comparing the Real-World Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Patients Hospitalized With COVID-19

Why Molnupiravir Fails in Hospitalized Patients

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study

Molnupiravir and Nirmatrelvir-Ritonavir: Oral COVID Antiviral Drugs

Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients

Molnupiravir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records